ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

At AAAS Meeting, David Baltimore Comments on Bush Administration Science Policy.

March 3, 2006

FDA Updates Safety Information for 5-Alpha Reductase Inhibitors

June 17, 2011

Governors Hear Pitch For State Cancer Control Increased Effort

August 3, 1979

Commercial Labs Open Drive To Get More NIH Business, Including Grants

April 26, 1974

2015 Breakthrough Prize Winners Announced at Gala

November 14, 2014

Coalition Members Urged To Demand Intent Of Congress In Cancer Act Be Recognized

March 13, 1981